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Mast syndrome is an autosomal recessive, complicated form of hereditary spastic paraplegia with dementia that is
present at high frequency among the Old Order Amish. Subtle childhood abnormalities may be present, but the main
features develop in early adulthood. The disease is slowly progressive, and cerebellar and extrapyramidal signs are
also found in patients with advanced disease. Patients have a thin corpus callosum and white-matter abnormalities,
as seen on magnetic resonance imaging. Using an extensive Amish pedigree, we have mapped the Mast syndrome
locus (SPG21) to a small interval of chromosome 15q22.31 that encompasses just three genes. Sequence analysis
of the three transcripts revealed that all 14 affected cases were homozygous for a single base-pair insertion (601insA)
in the acid-cluster protein of 33 kDa (ACP33) gene. This frameshift results in the premature termination (fs201-
212X213) of the encoded product, which is designated “maspardin” (Mast syndrome, spastic paraplegia, autosomal
recessive with dementia), and has been shown elsewhere to localize to intracellular endosomal/trans-Golgi trans-
portation vesicles and may function in protein transport and sorting.
Introduction
The hereditary spastic paraplegias (HSPs) are a clinically
diverse group of disorders that share the primary feature
of progressive lower-limb spasticity and weakness. These
disorders are classified as “pure,” when spasticity occurs
in isolation, and as “complicated,” when additional neu-
rological or other manifestations are present (McDermott
et al. 2000). In addition to the marked clinical variability,
HSP is genetically heterogeneous, with 11 autosomal
dominant, 7 autosomal recessive, and 3 X-linked forms
of the disease mapped (HUGO Gene Nomenclature Com-
mittee). HSP pathology involves degeneration of the long-
est corticospinal and dorsal column axons, which is maxi-
mal in their distal portions. Despite the identification of
genes for 9 of the 21 forms of the condition currently
mapped, the pathogenic basis of the HSPs remains un-
certain. Although the function of these genes appears to
be divergent, there is accumulating evidence to support
aberrant subcellular transportation and protein sorting as
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a common mechanism for a number of forms of motor
neuron degeneration (Crosby and Proukakis 2002).
Mast syndrome (MIM 248900) is a complicated form
of HSP in which progressive spastic paraparesis is as-
sociated in more advanced cases with dementia and
other CNS abnormalities (Cross and McKusick 1967).
Mast syndrome occurs with high frequency in the Old
Order Amish, a population that constitutes a genetic
isolate in which a number of disorders have been shown
to arise from an ancestral founder mutation, including
Troyer syndrome, another complicated form of HSP
(Patel et al. 2002). In the current study, we present clini-
cal and radiological findings from 14 patients with Mast
syndrome and the mapping and identification of the
causative mutation in the ACP33 gene (National Center
for Biotechnology Information [accession number NM_
016630]), the protein product of which has been shown
to associate with intracellular transportation vesicles.
Methods
Linkage Analysis
The genomewide linkage analysis was performed with
the ABI LMS, version 2.5, with an ABI 3100 sequence
analyzer and Genotyper software, v3.7. Marker satu-
ration analysis was performed using existing and novel
microsatellite markers. Alleles were size fractionated with
8% polyacrylamide gels, and DNA was visualized by
silver staining. Multipoint LOD scores were generated
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Table 1
Clinical Features of Patients with Mast Syndrome
CHARACTERISTIC
PATIENT NUMBER
3 4 8 9 14 17 20 23 26 27 31 32 36 39
Age at exam (years) 64 62 48 52 50 51 43 58 62 60 37 39 48 31
Milestone delay NK NK       NK   /  /
Personality/psychiatric problems              
Walking difficultiesa              
Dementia severity              
Dysphagia              /
Brisk jaw jerk    NK      NK   / 
Pyramidal signs (ULb)    NK          
Pyramidal signs (LLc)    NK          
Primitive reflexes    NK          
Cerebellar signs NK NK   NK NK  NK NK NK NK   
Extrapyramidal movements              
MMTSd 0 0 … … … 0 … … … … 0 9 6 14
NOTE.—Findings are graded by relative severity:  p absent; / p equivocal;  p mild;  p moderate;  p severe. NK p not
known (either owing to inadequate historical information or owing to inability to comply with exam).
a  p can walk without aid;  p can walk with walker;  p unable to walk.
b UL p upper limbs.
c LL p lower limbs.
d MMTS p mini mental test score (of 30).
using GENEHUNTER, v2.1, and the pedigree was de-
constructed to facilitate computational efficiency. An au-
tosomal recessive mode of inheritance with complete
penetrance and a disease gene frequency of 0.039 were
assumed.
Mutation Analysis
Intronic primers were designed flanking each of the nine
exons of the ACP33 gene, as well as those of the other
genes located within the critical interval. PCR was per-
formed using 50 ng genomic DNA and 5 pmol for each
primer. Amplified products were examined on 2% agarose
gels and purified for sequencing with a GENECLEAN
Turbo for PCR Kit (Q-BIOgene). PCR products were
sequenced with the ABI PRISM BigDye Terminator Cy-
cle Sequencing Ready Reaction Kit (Applied Biosystems)
and run on an ABI3100 sequence analyzer.
For SSCP analysis, PCR products from exon 4 of the
ACP33 gene were electrophoresed, using 0.55#MDE
(National Diagnostics) gels for 18 h at 10C (constant
250 V), with BioRad Protean II equipment. DNA was
visualized by silver staining.
Structure Modeling
Sequences were retrieved through ESTHER (Cousin et
al. 1998), and 3D-PSSM (Kelley et al. 2000) was used to
predict structural features. The model was built by side-
chain replacement with SCWRL (Bower et al. 1997), and
the figure was prepared using SwissModel (Guex and
Peitsch 1997).
Results
Clinical and Radiological Findings
History and Clinical Examination.—We investigated 29
family members, of whom 14 were affected with Mast
syndrome and 1 had been part of the original study (Cross
and McKusick 1967) (table 1). The ages of patients ex-
amined had a range of 31–62 years (mean age 51.79
years). The condition was clearly progressive in all 29
family members, leading to akinetic mutism in the most
severely affected subjects. A slight delay in milestones
was reported in those for whom information was avail-
able. Problems were usually noted in childhood, with
difficulties at school, although most were able to com-
plete 8th grade. Motor difficulties were also noted during
childhood in some cases, with mild incoordination and
awkward running. Patients were perceived as relatively
normal in teenage years and early adulthood, and several
were married, had children, obtained driving licenses,
and held jobs. It is difficult to precisely define the onset
of decline in walking and mental function, but, for many,
this was already evident by the early 20s; in others, there
is no clear history of a decline before the late 30s or
early 40s. Speech declined progressively, but the char-
acter of speech was not reported as significantly affected.
Early subtle personality disturbances were reported in sev-
eral individuals who were always shy, nervous, or “not
very talkative,” and, in three individuals, clear psychotic
episodes had occurred (bipolar disorder, paranoid ide-
ation, or hearing voices). Seizures were reported in two
cases but had subsided spontaneously. Progressive dif-
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Figure 1 MRI of patient 17, showing thin corpus callosum and cerebral atrophy (A) and periventricular white-matter hyperintensity (B)
ficulties in swallowing arose, often necessitating percu-
taneous enterogastrostomy feeding.
Examination revealed clear pyramidal signs in all sub-
jects, with hypertonicity, brisk reflexes, and extensor plan-
tars; these were more severe in the lower than in the
upper limbs. In the most advanced cases, legs were rigid,
with no spontaneous movements and very little passive
flexion, and the patients were bedbound. Higher mental
function was significantly impaired in all patients, and
even those who were able to answer certain questions
were apathetic, with paucity of facial expression, and were
very difficult to engage in conversation. Mini mental test
score was 0/30 in advanced cases and was only 14/30
in the youngest affected individual. For all individuals
studied, speech was very limited where present, but it
sounded only mildly dysarthric and was quite easy to
understand. Primitive reflexes were found in patients with
more advanced disease. Cerebellar dysfunction (incoor-
dination and disdiadochokinesia but no nystagmus) was
demonstrated in subjects with mild-to-moderate disease;
assessment was not possible in the most severely affected
subjects. Extrapyramidal movements (oromandibular
dyskinesia and athetoid movements of the fingers or en-
tire limbs) were seen in three advanced cases. Sensation
was normal where it could be tested, but diminished
ankle jerks in two subjects with advanced disease indi-
cated that a peripheral neuropathy could not be ex-
cluded in later stages.
Investigations
Magnetic resonance imaging (MRI) brain scans were
available for patient 8 at age 46 years (fig. 1), patient 17
at age 47 years, and patient 32 at age 31 years. All MRIs
showed a thin corpus callosum, cerebral and cerebellar
atrophy, and white-matter hyperintensity compatible
with demyelination. Patient 17 also had a frontal lesion,
likely to be an incidental meningioma. She had been
previously diagnosed as having a leucodystrophy, but
very-long-chain fatty acids and arylsulfatase A were nor-
mal. Nerve-conduction studies performed at age 35 years
had revealed no abnormality.
Mapping of the Mast Syndrome Locus (SPG21)
to Chromosome 15q22
After exclusion of the known autosomal recessive HSP
loci on chromosomes 3q27-q28, 8p12-q13, 14q22-q24,
15q13-q15, and 16q24.3 by linkage analysis (data not
shown), DNA from 8 of the 14 affected individuals with
Mast syndrome was used to conduct a genomewide
screen for linkage, under the assumption that a founder
mutation was responsible for the condition. Genotyping
with the LMS2 marker set revealed only a single signifi-
cant region of homozygosity, located on chromosome 15q
in the region of marker D15S153. Subsequent analyses—
by utilization of a total of 16 novel and existing micro-
satellite markers and incorporation of the remaining af-
fected subjects and unaffected parents and siblings—iden-
tified the presence of an ancestral chromosome on which
the causative mutation resides (table 2). When examined
in parallel, recombination events in the affected cases
identify a single block of homozygosity that encom-
passes markers repeat 1, repeat 2, and repeat 3 (table
2). The apparent homozygosity of these markers in un-
affected individuals 7, 11, and 35 (fig. 2) can be clearly
explained by extended haplotype analysis, which shows
that the homozygosity results from partial informativity
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Table 2
Haplotype Analysis of Affected Individuals in Large Amish Pedigree
LOCATION
HAPLOTYPES IN AFFECTED INDIVIDUAL
3 4 8 9 14 17 20 23 26 27 31 32 36 39
D15S1033 3, 5 3, 1 1, 4 4, 4 1, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 1 4, 4
D15S1036 2, 1 2, 3 2, 2 2, 2 1, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 5 2, 2
D15S993 1, 3 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 2 1, 1
D15S1018 3, 1 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3
D15S1009 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1
D15S108 2, 5 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2
Repeat 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1
Repeat 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2
ACP33 601insA 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1
Repeat 3 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4 4, 4
D15S1507 1, 3 3, 1 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3
D15S1020 3, 1 1, 3 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1
D15S153 5, 3 3, 5 3, 3 3, 3 3, 3 3, 3 3, 4 3, 4 3, 3 3, 3 3, 3 3, 3 3, 3 3, 3
D15S125 3, 1 1, 3 1, 1 1, 1 1, 1 1, 1 1, 2 1, 2 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1
D15S988 2, 1 1, 2 1, 1 1, 1 1, 1 1, 1 1, 2 1, 2 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1
D15S983 8, 1 1, 8 1, 2 1, 2 1, 1 1, 1 1, 3 1, 3 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1
D15S1025 2, 2 2, 2 2, 3 2, 3 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 2 2, 3
D15S1000 3, 1 1, 3 1, 3 1, 3 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1 1, 1
NOTE.—Analysis reveals the mutation-bearing ancestral chromosome (shown in boldface italics) and recombination events
delimiting the common region of homozygosity (underlined). Repeat 1 is a GATA repeat, and repeat 2 is a TA repeat; both were
identified in BAC clone AC069368. Repeat 3 is an AAAT repeat located in BAC clone AC103691.
of these markers and that they are not identical by de-
scent. This result was further confirmed by mutation
analysis (see below). Recombination events in the an-
cestral chromosome were identified proximally in indi-
viduals 3, 4, 8, 14, and 36—with individual 3 being
delimiting—and distally in individuals 3, 4, 8, 9, 20, 23,
and 39—with individuals 3 and 4 being delimiting (table
2). Taken together, the haplotype analysis indicates that
the Mast syndrome locus resides within a 156-kb inter-
val situated between markers D115S108 and D15S1507.
Multipoint linkage analysis—by use of GENEHUNTER,
v2.1, with 100% penetrance and a trait-allele frequency
of 0.039—conclusively confirmed linkage to this region,
yielding a maximum LOD score of 15.1 (fig. 3).
Mutation Analysis
The 156-kb interval of band 15q22.31 contains three
nonoverlapping transcriptional units listed from centro-
mere to telomere: the ankyrin domain-containing protein
LOC348094, an acid-cluster protein of 33 kDa (ACP33),
and the mitochondrial methionyl-tRNA formyltransfer-
ase (MtFMT) (fig. 4). For all three transcripts, primers
were positioned to incorporate each exon and its asso-
ciated splice signals and were used to sequence genomic
DNA from an affected individual and an unaffected par-
ent. We identified a single nucleotide insertion (601insA)
in exon 7 of the ACP33 gene (fig. 5), which is predicted
to produce a frameshift causing substitution of the fol-
lowing 12 amino acids and premature termination of
translation (fs201-212X213) of the protein product mas-
pardin (Mast syndrome, spastic paraplegia, autosomal re-
cessive with dementia). Sequence analysis revealed that
this mutation cosegregates perfectly with the disease in
this population, since unaffected siblings are either ho-
mozygous wild-type or heterozygous carriers. This mu-
tation was not detected in 236 normal control chromo-
somes of mixed white (80%), Asian (10%), and African
(10%) descent, and only one carrier of the mutation was
identified in 64 chromosomes originating from the same
Amish community in which this condition is present at
high frequency.
Comparative Protein Alignment and Structural
Predictions
To determine whether maspardin is likely to possess
enzymatic function, we have conducted alignment of mas-
pardin with a typical hydrolase molecule (chloroperoxi-
dase, PRXC_PSEFL). Although it is clear from this align-
ment that maspardin is a member of this superfamily
(fig. 6), the nucleophile-acid-histidine triad required for
catalytic function is not present, which suggests that mas-
pardin is unlikely to be an enzyme. This is further con-
firmed by modeling of maspardin on the basis of the re-
sults of 3D-PSSM, with 1A8S as a template (fig. 7). This
reveals that only one of the residues required for catalysis
is present (ser109) and that Asp 226 (located adjacent
to Gln 227) points in the wrong orientation.
Discussion
Mast syndrome (SPG21) is an autosomal recessive com-
plicated form of HSP associated with dementia and mild
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Figure 3 Multipoint LOD scores for markers situated across the SPG21 locus, flanked by markers D15S108 and D15S1507, producing
a peak score of 15.1 for marker repeat 3.
Figure 4 A schematic transcript map of the SPG21 locus, located within contig NT_010265 and spanning BAC clones AC069368,
AC013691, and AC013553 (NCBI). The relative positions of the markers used for haplotyping, transcripts (and direction of transcription)
located within and around the critical region, and the 601insA mutation in ACP33 are shown.
developmental, pseudobulbar, cerebellar, and extrapyr-
amidal abnormalities, first described at high frequency in
an Old Order Amish deme (Cross and McKusick 1967).
Mild early milestone delay and subtle cognitive and mo-
tor difficulties in childhood are often reported, indicating
a neurodevelopmental problem. Symptom progression
usually commences in early adulthood and is slow but
relentless, suggesting ongoing neurodegeneration affect-
ing several different areas of the CNS. Although there
is no evidence of peripheral nerve involvement, brain
MRI reveals a thin corpus callosum, together with gray-
matter atrophy and white-matter demyelination (fig. 1).
The clinical pattern and radiological findings suggest a
pattern of degeneration more widespread than that of
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Figure 5 Sequence chromatograms of the region around the exon
7 601insA mutation (arrow) of ACP33 in a wild-type homozygote (A),
a homozygous affected individual (B), and a carrier parent (C).
the axons of the corticospinal tracts and the posterior
columns that degenerate in pure HSP.
The corpus callosum abnormality, which is part of
many inherited syndromes (Dobyns 1996), is particu-
larly interesting and may represent partial agenesis, at-
rophy, or a combination of both. A developmental ab-
normality would explain the slight delay in milestones
and the subtle problems in intellect and coordination seen
early in life. White-matter abnormalities and a thin cor-
pus callosum have only rarely been reported in some
forms of HSP, including SPG11 (McDermott et al. 2000),
an autosomal recessive form of the disease (Martinez
Murillo et al. 1999). HSP complicated by dementia is
also relatively unusual, although a mild intellectual im-
pairment, possibly progressive, has been reported in HSP
caused by SPG4 (spastin) mutations (Byrne et al. 2000).
Conversely, there are reports of adult-onset dementias
accompanied by spastic paraparesis, including Alzheimer
disease, caused by presenilin-1 mutations (Houlden et al.
2000), and a variant of the Gerstmann-Stra¨ussler syn-
drome, an inherited prion disease (Kitamoto et al. 1993).
However, these conditions differ from Mast syndrome in
that they lack a developmental phenotype, and Mast syn-
drome is almost certain to have a pathology distinct from
both of them.
The identification of the 601insA mutation in the
ACP33 gene is expected to produce a frameshift, gen-
erating a premature stop codon, which is likely to result
in a loss of function of the polypeptide product assigned
the more phenotypically descriptive alias “maspardin.”
The facts that the remaining genes located in the Mast
syndrome interval contained no disease-associated mu-
tations and that we did not detect the 601insA mutation
in a large number of controls strongly suggest that this
is the causative mutation. To date, only one functional
study relating to maspardin is available in which the
molecule was identified through its association with CD4,
a cell-surface glycoprotein involved in the cellular im-
mune response; therefore, the study focused specifically
on this interaction (Zeitlmann et al. 2001). The subcel-
lular localization of the protein was investigated, using
a monoclonal antibody directed against the complete
polypeptide in HUT78 (CD4-positive T cell line) cells
and using a chimeric fusion protein (Zeitlmann et al.
2001). These results revealed that both endogenous and
transiently expressed proteins are cytosolic and that
they partially associate with particulate structures. Sub-
sequent studies revealed that the vesicular structures
marked by maspardin partially coincided with those
marked for transferrin—which is confined to the early
endosomal recycling pathway—and with acidic organ-
elles, suggesting that maspardin is partitioned between
the cytosol and vesicles of the endosomal/trans-Golgi
network. Taken together, it appears that maspardin may
be involved in the sorting and/or trafficking of molecules
in HUT78 cells (Zeitlmann et al. 2001).
Although our BLAST homology searches indicate no
known subcellular localization signals, leader sequence,
or transmembrane regions, they did reveal a clear but
limited similarity to the a/b hydrolases that mainly com-
prise enzymes that catalyze a diverse range of reactions
(Holmquist 2000). Previous studies have indicated that
the a/b hydrolases can be delineated by the presence of
three essential structural features required for catalysis:
the presence of at least five parallel b strands, a catalytic
triad in a specific order (nucleophile-acid-histidine), and
a nucleophile elbow (Shaw et al. 2002). Although our
alignment studies indicate that maspardin is clearly re-
lated to members of this superfamily and possesses a nu-
cleophilic elbow and parallel b strands, it does not pos-
sess the catalytic triad, which suggests that it is unlikely
to possess enzymatic function (figs. 6 and 7). Further
support for this is provided by studies of the hydrolase
fold of maspardin. The hydrolase fold comprises a nu-
cleophile elbow with a nucleophilic residue at its center
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Figure 6 Alignment of maspardin with pseudomonas fluorescens chloroperoxidase (SwissProt: O31158 PRXC_PSEFL, PDB:1A8S). Line
1 shows the predicted secondary structure (“C3” loop, “E” strand, and “H” helix); lines 2 and 3 show the sequence of maspardin and
chloroperoxydase, respectively; line 4 shows the known secondary structure of PRXC_PSEFL; and line 5, CORE, is a measure of the burial
and number of contacts made by each residue, on a scale between 0 (not buried/few contacts) and 9 (very buried/many contacts). Amino acids
of the catalytic triad of PRXC_PSEFL are shown in bold and are marked by an asterisk (*).
(Holmquist 2000), which corresponds to residue 109
(serine) of maspardin. A single point mutation disrupt-
ing the nucleophilic elbow (serine109alanine) was suf-
ficient to completely abolish interaction with CD4 (Zeitl-
mann et al. 2001). Consequently, it appears that the hy-
drolase-related domain of maspardin has evolved from
an ancient enzymatic function and is now likely to serve
as an intracellular protein-protein interaction module.
Two families of noncatalytic a/b hydrolase fold proteins
have been described elsewhere: the electrotactins—
which include the neural cell adhesion proteins glio-
tactin, neurotactin, and neuregulin (Botti et al. 1998)—
and the N-myc downstream regulated (NDRG) proteins
NDRG1–NDRG4 (Qu et al. 2002; Shaw et al. 2002).
Of particular interest in the context of Mast syndrome
is the identification of a nonsense mutation in NDRG1,
shown elsewhere to underlie hereditary motor and sen-
sory neuropathy-Lom (HMSNL), an autosomal reces-
sive peripheral neuropathy with early axonal involve-
ment possibly resulting from impaired axonal-glial
interactions (Kalaydjieva et al. 2000). HMSNL shows
no features suggestive of upper motor neuron involve-
ment (Kalaydjieva et al. 1998), and, conversely, there
was no clear evidence of lower motor neuron involve-
ment in Mast syndrome. Mutations in similar molecules
causing other pure forms of HSP, an upper motor neu-
ron disease, and HMSN, a lower motor neuron disease,
have been described elsewhere in the kinesins micro-
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Figure 7 Model of the structure of maspardin on the basis of the results of 3D-PSSM, with 1A8S as a template, which indicates that two
of the three residues (Gln227 and Asn255) do not conform to the a/b hydrolase catalytic triad and that Asp226 is in the opposite orientation.
Alpha helices are shown in yellow, and beta strands are shown in blue.
tubule motor proteins: KIF5A mutations lead to a pure
form of HSP (Reid et al. 2002), and KIF1Bb mutations
lead to HMSNIIA (Zhao et al. 2001). Consequently, the
identification of mutations in two nonenzymatic hydro-
lases, associated with two motor neuron degenerative
phenotypes, suggests a related function of these mole-
cules that is essential for neuronal survival and high-
lights these molecules as candidates for other inherited
forms of neurodegeneration.
There is now increasing direct and circumstantial evi-
dence to support the hypothesis that defective protein
sorting and trafficking underlies a range of neurodege-
nerative conditions (Crosby 2003) and that defective
trafficking may be a final pathway common to a number
of genes involved in HSP (Crosby and Proukakis 2002).
Neurons possess a unique morphology, typically char-
acterized by an extensive branching dendritic tree and
a single long axon (spinal motor neuron axons reach 1
m in length), and these cell processes typically contain
the bulk of the cytoplasm of the cell; yet protein manu-
facture, packaging, and sorting is essentially restricted
to the cell body. In consequence, these factors place
tremendous demands on intracellular transport sys-
tems, which may constitute a “weak link” susceptible
to various insults, resulting in neurodegenerative dis-
eases. Although the role of maspardin is not clear and
now warrants detailed investigation, the studies de-
scribed above are consistent with an involvement in
vesicle-mediated trafficking and protein sorting. There-
fore, Mast syndrome may represent an example of an-
other condition in which disruption of these mechanisms
leads to neurodegeneration.
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